Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortho Evra Heart Attack/Stroke Risk Final Results Due In 2007, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Preliminary analysis suggests two-fold greater risk of blood clots associated with J&J/Ortho-McNeil's transdermal contraceptive patch than with traditional oral contraceptives.

You may also be interested in...



Ortho Evra Label Update Includes Study Data On Blood Clot Risk

FDA requests J&J conduct longer follow up studies on the risk of serious blood clots, heart attack and stroke associated with the birth control patch.

Ortho Evra Label Update Includes Study Data On Blood Clot Risk

FDA requests J&J conduct longer follow up studies on the risk of serious blood clots, heart attack and stroke associated with the birth control patch.

Ortho-McNeil Conducting Additional Studies To Assess Ortho Evra Blood Clotting Risks

The firm updated labeling to include a new bolded warning regarding increased hormone exposure with the patch versus oral contraceptives.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel